ImmunityBio (NASDAQ:IBRX) is a biotechnology company focused on developing advanced therapies for cancer and infectious diseases. Its main product is Anktiva, a treatment for certain types of bladder cancer. The company is scheduled to release its next quarterly earnings report on May 11, 2026, with analysts expecting an earnings per share (EPS) of -$0.08 and revenue of about $43.07 million.
In its most recent first-quarter results, ImmunityBio reported sales of $44.21 million, surpassing the consensus estimate. This represents a significant 168% increase from the $16.52 million reported in the same quarter a year ago. The growth was driven by a 168% rise in unit sales volume for its drug, Anktiva.
Despite the strong revenue, the company reported a loss of -$0.62 per share. This was a much larger loss than the consensus estimate of a -$0.07 loss. As highlighted by Benzinga, this earnings miss caused the stock to trade 11.46% lower, even with the record revenue growth.
The company also faces regulatory issues. In April, the FDA issued a warning to ImmunityBio for making what it called unsupported claims about Anktiva's effectiveness. This led to a securities class action lawsuit, as highlighted by GlobeNewswire, covering investors who acquired securities between January 19, 2026, and March 24, 2026.
Looking at its financial health, ImmunityBio has a negative price-to-earnings (P/E) ratio of -10.23, which indicates the company is not currently profitable. However, its price-to-sales (P/S) ratio is 62.06. This ratio compares the stock price to its revenues and suggests investors are paying a high price for each dollar of sales.
The company's debt-to-equity ratio is -0.05, showing it has very little debt compared to its shareholder equity. Furthermore, its current ratio of 6.67 indicates a strong ability to meet its short-term financial obligations, as its current assets are more than six times its current liabilities.
